Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

Abstract Background Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Approaches to combine immunotherapies and targeted therapies to overcome or dela...

Full description

Bibliographic Details
Main Authors: Deborah Ayeni, Braden Miller, Alexandra Kuhlmann, Ping-Chih Ho, Camila Robles-Oteiza, Mmaserame Gaefele, Stellar Levy, Fernando J. de Miguel, Curtis Perry, Tianxia Guan, Gerald Krystal, William Lockwood, Daniel Zelterman, Robert Homer, Zongzhi Liu, Susan Kaech, Katerina Politi
Format: Article
Language:English
Published: BMJ Publishing Group 2019-07-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Lung cancer
EGFR
Targeted therapies
Immunotherapies
Mouse models
Online Access:http://link.springer.com/article/10.1186/s40425-019-0643-8

Internet

http://link.springer.com/article/10.1186/s40425-019-0643-8

Similar Items